Chabak Vaccine Research Institute Receives Domestic Approval for Phase 1 Clinical Trial of 3rd Generation Hepatitis B Vaccine

[Asia Economy Reporter Jihee Kim] ChabioTech affiliate Chavaccine Research Institute announced on the 17th that it has received approval from the Ministry of Food and Drug Safety for a domestic Phase 1 clinical trial plan to confirm the preventive effect of the 3rd generation hepatitis B vaccine.

The clinical trial is scheduled to be conducted until October 2023, targeting adults aged 19 to under 65.

Chavaccine Research Institute's hepatitis B vaccine 'CVI-HBV-002' received approval from the Ministry of Food and Drug Safety in May 2014 for the purpose of a 'therapeutic' vaccine and conducted Phase 1 and 2a clinical trials targeting chronic hepatitis B patients. In October 2019, it received approval for Phase 2b clinical trials, which are currently ongoing. Chavaccine Research Institute judged that this vaccine could be developed as a preventive vaccine in addition to its therapeutic purpose and obtained approval for a domestic clinical trial plan as a preventive vaccine this time.

Chavaccine Research Institute's hepatitis B vaccine includes 3rd generation antigens and a proprietary immune adjuvant. The institute expects the efficacy of the 3rd generation vaccine to be higher as the 3rd generation antigen has higher immunogenicity than the 2nd generation antigen.

Yeom Jeong-seon, CEO of Chavaccine Research Institute, said, "Based on our immune adjuvant platform technology, we will lead Chavaccine Research Institute as a competitive biotechnology company developing not only preventive vaccines but also therapeutic vaccines and anticancer treatments through continuous research and development."

Meanwhile, Chavaccine Research Institute is proceeding with a KOSDAQ listing within this year through a technology special case method. After passing the technology evaluation in March, it filed a preliminary review for listing with the Korea Exchange in April.